This is a preview of subscription content, log in via an institution to check access.
Notes
2018 US dollars
Reference
Xin W, et al. Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial. BMJ Open : 18 Dec 2020. Available from: URL: http://dx.doi.org/10.1136/bmjopen-2020-038867
Rights and permissions
About this article
Cite this article
Pembrolizumab not cost effective for platinum-resistant HNSCC. PharmacoEcon Outcomes News 869, 23 (2021). https://doi.org/10.1007/s40274-021-7390-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7390-z